Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer

Summary

It is a an open label, multicentric, phase II study assessing the efficacy of everolimus (given per os) as a first line treatment in kidney cancer of bad prognosis. 92 patients will be included (anticipated). The treatment by everolimus will continue until progression, significant toxicity or withdraw of consent

Timeline

Start

2011-07

Primary completion

2014-07

Completion

2014-07

Drugs

Indications